Caspofungin indications and usage: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) Created page with "__NOTOC__ {{Caspofungin}} {{CMG}}; {{AE}} {{AZ}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CANCIDAS (CASPOFUNGIN ACETATE) INJECTION, POWDE..." |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
==Indications and Usage== | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CANCIDAS (CASPOFUNGIN ACETATE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3bad23a6-09a6-4194-9182-093ed61bc71c | publisher = | date = | accessdate = }}</ref> | CANCIDAS® is indicated in adults and pediatric patients (3 months and older) for: | ||
*:Empirical therapy for presumed fungal infections in febrile, [[neutropenic]] patients | |||
*:Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, [[peritonitis]] and pleural space infections. CANCIDAS has not been studied in [[endocarditis]], [[osteomyelitis]], and [[meningitis]] due to Candida. | |||
*:Treatment of esophageal [[candidiasis]] | |||
*:Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies (e.g., amphotericin B, lipid formulations of amphotericin B, itraconazole). CANCIDAS has not been studied as initial therapy for invasive aspergillosis.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CANCIDAS (CASPOFUNGIN ACETATE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [MERCK SHARP & DOHME CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3bad23a6-09a6-4194-9182-093ed61bc71c | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Revision as of 03:40, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Indications and Usage
CANCIDAS® is indicated in adults and pediatric patients (3 months and older) for:
- Empirical therapy for presumed fungal infections in febrile, neutropenic patients
- Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. CANCIDAS has not been studied in endocarditis, osteomyelitis, and meningitis due to Candida.
- Treatment of esophageal candidiasis
- Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies (e.g., amphotericin B, lipid formulations of amphotericin B, itraconazole). CANCIDAS has not been studied as initial therapy for invasive aspergillosis.[1]
References
Adapted from the FDA Package Insert.